Janux Therapeutics, Inc.Janux Therapeutics, Inc.Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪2.58 B‬USD
−1.34USD
‪−58.29 M‬USD
‪8.08 M‬USD
‪34.43 M‬
Beta (1Y)
4.44

About Janux Therapeutics, Inc.

CEO
David Campbell
Headquarters
San Diego
Employees (FY)
64
Founded
2017
ISIN
US47103J1051
FIGI
BBG00ZHSKH11
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of JANX is 52.65 USD — it has increased by 5.30% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Janux Therapeutics, Inc. stocks are traded under the ticker JANX.
Janux Therapeutics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Janux Therapeutics, Inc. has a max estimate of 100.00 USD and a min estimate of 25.00 USD.
JANX earnings for the last quarter are −0.25 USD whereas the estimation was −0.47 USD which accounts for 46.81% surprise. Estimated earnings for the next quarter are −0.42 USD. See more details about Janux Therapeutics, Inc. earnings.
Janux Therapeutics, Inc. revenue for the last quarter amounts to ‪2.52 M‬ USD despite the estimated figure of ‪845.50 K‬ USD. In the next quarter revenue is expected to reach ‪750.00 K‬ USD.
Yes, you can track Janux Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, JANX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Janux Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
JANX reached its all-time high on Feb 28, 2024 with the price of 58.69 USD, and its all-time low was 5.65 USD and was reached on Nov 10, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 13, 2024, the company has 64.00 employees. See our rating of the largest employees — is Janux Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Janux Therapeutics, Inc. EBITDA is ‪−71.02 M‬ USD, and current EBITDA margin is −878.68%. See more stats in Janux Therapeutics, Inc. financial statements.